Artivion (NYSE:AORT) Issues Quarterly Earnings Results

Artivion (NYSE:AORT) issued its earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14, FiscalAI reports. The firm had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.

Here are the key takeaways from Artivion’s conference call:

• Third-quarter revenue grew 9% year over year in constant currency, led by 12% growth in stent grafts and 13% growth in On-X valves. Management said On-X supply has improved after manufacturing investments, while acknowledging that adjusted EBITDA fell 8% and gross margin declined.
• Artivion narrowed its 2026 outlook to 8%–10% adjusted constant-currency revenue growth and $93 million–$98 million of adjusted EBITDA. Management cited a Q4 currency headwind and an expected reversal of unusually strong preservation-services revenue; it also forecast PerClot’s departure to reduce 2027 revenue growth by about 2 percentage points and EBITDA growth by 4 points.
• AMDS implants increased following U.S. PMA approval, but starter-set sales remain slow because hospitals face administrative hurdles around the roughly $100,000 upfront purchase. Management said it is working to ease those barriers, but expects account adoption to take time.
• NEXUS preparations are progressing toward a planned U.S. launch on January 1, 2027, with surgeon interest, training, inventory-building, and sales-team expansion underway. Management expects sales to ramp gradually through 2027 and anticipates the combined business will be EBITDA-neutral for the year.
• The ARTIZEN trial for the Arcevo LSA platform has enrolled 56 patients, with enrollment completion expected in mid-2027. Management expects to present initial results from the first 30 patients and, if the trial succeeds, anticipates FDA approval in 2029.

Artivion Trading Down 20.1%

AORT traded down $5.09 during trading on Friday, reaching $20.23. The company had a trading volume of 3,246,962 shares, compared to its average volume of 486,118. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion has a 52 week low of $19.16 and a 52 week high of $48.25. The stock has a market cap of $986.66 million, a P/E ratio of 43.67 and a beta of 1.31. The business has a 50 day simple moving average of $23.55 and a 200-day simple moving average of $28.98.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AORT. Citigroup restated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Jefferies Financial Group assumed coverage on Artivion in a research note on Tuesday, October 20th. They set a “buy” rating and a $31.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Canaccord Genuity Group dropped their price target on shares of Artivion from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.57.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 977 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James P. Mackin sold 70,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the sale, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. The trade was a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 90,460 shares of company stock worth $2,557,366. Insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.